Lung Cancer |

Advanced Non-small Cell Lung Cancer in Elderly Patients: The Standard Every 3-Weeks Versus Weekly Paclitaxel With Carboplatin FREE TO VIEW

Amal Fathy, DMD; Hala El-shenshawy, MD; Eman El-zahaf, MD; Saleh Taema, MD; Doaa Sharaf Eldeen, MD; Wafaa El-Beshbeshi, MD
Author and Funding Information

Mansoura University Thoracic Medicine department, Mansoura, Egypt

Chest. 2013;144(4_MeetingAbstracts):652A. doi:10.1378/chest.1701591
Text Size: A A A
Published online


SESSION TITLE: Lung Cancer Posters

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Wednesday, October 30, 2013 at 01:30 PM - 02:30 PM

PURPOSE: to evaluate the efficacy and safety of weekly paclitaxel combined with carboplatin compared with the classic 3-weekly schedule of paclitaxel and carboplatin as initial therapy and the feasibility of subsequent maintenance therapy versus observation in elderly patients with locally advanced (stage IIIB) and metastatic (stage IV) NSCLC.

METHODS: Ninty patients P65 years with stage IIIB-IV NSCLC were randomly assigned to one of the following arms: arm1, paclitaxel 90 mg/m2 weekly for 3 of 4 weeks with carboplatin (area under the curve {AUC} =6) on day 1 of each 4 week cycle; and arm 2, paclitaxel 200 mg/m2 with carboplatin (AUC = 6) on day 1 of each 3-week. After four cycles of chemotherapy, those with objective response or stable disease were randomized to weekly paclitaxel (70 mg/ m2, 3 of 4 weeks) or observation as maintenance therapy. Primary end point was response while second end points included survival and toxicity.

RESULTS: Eighty-six patients were evaluable for response, overall responses were recorded in 42.9% in arm 1 versus 31.8% in arm 2; stable disease was 38.1% in arm 1 versus 27.3% in arm 2 and progressive disease was 19% in arm 1 versus 40.9% in arm 2. The median time to progression and median survival times were 7 months and 10.8 months in arm 1 versus 5.6 months and 9 months in arm 2, respectively. The 1-year survival rates were 47.6% in arm 1 versus 36.4% in arm 2. Grade 3/4 anemia was more common in arm 1 (23.8%) than arm 2 (9.1%). Grade 3/4 neutropenia and febrile neutropenia occurred in 14.3% and 4.7% in arm 1 versus 22.7% and 9.1% in arm 2. Grade 2/3 neuropathy occurred in 4.7% in arm 1 versus 13.6% in arm 2.

CONCLUSIONS: Efficacy was similar between the weekly regimen and the standard regimen of carboplatin and paclitaxel for elderly patients with advanced NSCLC and may be advantageous based on its favorable tolerability profile.

CLINICAL IMPLICATIONS: Treatment of advanced NSCLC is palliative; the aim is to prolong survival with less deterioration in quality of life

DISCLOSURE: The following authors have nothing to disclose: Amal Fathy, Hala El-shenshawy, Eman El-zahaf, Saleh Taema, Doaa Sharaf Eldeen, Wafaa El-Beshbeshi

No Product/Research Disclosure Information




Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543